Cargando…

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

INTRODUCTION: The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress. METHODS: T2 Protect AD (T2), a phase 2 randomized placebo‐controlled trial of trori...

Descripción completa

Detalles Bibliográficos
Autores principales: Shadyab, Aladdin H., LaCroix, Andrea Z., Matthews, Genevieve, Bennett, Daniel, Shadyab, Alexandre A., Tan, Donna, Thomas, Ronald G., Mason, Jennifer, Lopez, Alex, Askew, Brianna, Donahue, Lia, Kaplita, Stephen, Qureshi, Irfan A., Huisa, Branko, Feldman, Howard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919121/
https://www.ncbi.nlm.nih.gov/pubmed/35310528
http://dx.doi.org/10.1002/trc2.12265